Premium
P3‐244: Biomarkers for risk of Alzheimer's disease: Modeling the severity of neurofibrillary tangles in the Hippocampus region
Author(s) -
Burnham Samantha C.,
Wilson William,
Kiiveri Harri,
Szoeke Cassandra,
Martins Ralph N.
Publication year - 2010
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2010.05.1743
Subject(s) - hippocampus , quartile , disease , medicine , pathology , confidence interval
(TTR) was one of the plasma proteins identified using LC/MS/MS which discriminated rapid from non-rapid progressors in the proteomics discovery phase; and found to be down regulated in the rapid progressors group. Further quantification of plasma TTR using ELISA in larger sample showed TTR to be decreased in the AD subjects presenting with rapid cognitive decline at the time of analysis (p 1⁄4 0.036). TTR concentration was also lower in persons with moderate-severe stage of AD (p < 0.01). TTR levels correlated with Mini Mental State Examination (MMSE) scores (p 1⁄4 0.006, r 1⁄4 0.2). And linear regression model showed TTR levels predicting loss of scores on MMSE over the next six months period (p 1⁄4 0.026 [95% CI, -0.02-0.01]), both in unadjusted model and after adjustment for age, gender, baseline MMSE scores, duration of illness and APOE4. Conclusions: A significant lower level of TTR was found in AD subjects who presented with faster cognitive decline and with more severe cognitive severity. TTR levels also predicted cognitive decline over the next 6 months. This suggests that plasma transthyretin may be a candidate marker for disease severity and progression in AD.